After screening, participants will undergo a 2-week run-in period where they will wear a continuous glucose monitor and ketone sensor and receive education about management of sustained hyperglycemia/ Clinical Trials
2 recruitingIntervention
Phase 22
Showing 1–2 of 2 trials
Recruiting
Phase 2
Evaluating Glucose Levels and Risk of Ketoacidosis in People with Type 1 Diabetes Receiving SGLT1/2 inhibitor Therapy Using a Novel Continuous Ketone Sensor; Exercise Sub-Study
Type 1 Diabetes
St Vincent's Hospital Melbourne24 enrolled3 locationsACTRN12624000992505
Recruiting
Phase 2
Evaluating Glucose Levels and Risk of Ketoacidosis in People with Type 1 Diabetes Receiving SGLT2 inhibitor Therapy Using a Novel Continuous Ketone Sensor
Type 1 Diabetes
St Vincent's Hospital Melbourne60 enrolled1 locationACTRN12624000448549